Xanthine oxidase inhibitor

A technology of compounds and solvates, applied in the field of xanthine oxidase inhibitors, can solve problems such as no reports yet

Inactive Publication Date: 2016-11-23
SHENYANG PHARMA UNIVERSITY
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] 2-(3-cyano/nitro-4-substituted phenyl)-4-methyl-2H-1,2,3-triazole-4-carboxylic acid

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Xanthine oxidase inhibitor
  • Xanthine oxidase inhibitor
  • Xanthine oxidase inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Example 1: Preparation of 2-(3-cyano-4-n-propoxyphenyl)-5-methyl-2H-1,2,3,-triazole-4-carboxylic acid (compound 1)

[0067] (1) Diazotization and condensation:

[0068] Crude 5-amino-2-n-propoxybenzonitrile (0.48 g, 2.6 mmol), 15% HCl solution (5 mL), was added to H 2 O (5mL), stirred for 30 minutes under ice-bath conditions; NaNO was slowly added dropwise to the system 2 (0.27g, 3.0mmol) of the aqueous solution, dripping finished, continue to react in ice bath for 30 minutes; Add the ethanol solution of ethyl acetoacetate (0.39g, 3mmol) in the system, then use the saturated aqueous solution of sodium acetate to adjust the pH of the system to Neutral, reacted for 30 minutes; a yellow solid was precipitated, suction filtered, the filter cake was washed with water, and dried to obtain crude ethyl 2-(3-cyano-4-n-propoxyphenylhydrazone)-3-oxobutanoate, which was collected as The rate is 83%.

[0069] (2) ring closure:

[0070] Crude ethyl 2-(3-cyano-4-n-propoxyphenylhyd...

Embodiment 2

[0074] Example 2: Preparation of 2-(3-cyano-4-isopropoxyphenyl)-5-methyl-2H-1,2,3,-triazole-4-carboxylic acid (compound 2)

[0075] Except using different raw materials, 2-(3-cyano-4-isopropoxyphenyl)-5-methyl-2H-1,2,3,-triazole was prepared in the same manner as in Example 1 -4-formic acid (compound 2), the total yield is 68% (based on raw material 4-isopropoxy-3-cyanoaniline), its structural formula, 1 H-NMR and MS data are listed in Table-1 below.

Embodiment 3

[0076] Example 3: Preparation of 2-(3-cyano-4-n-butoxyphenyl)-5-methyl-2H-1,2,3,-triazole-4-carboxylic acid (compound 3)

[0077] Except using different raw materials, 2-(3-cyano-4-n-propoxyphenyl)-5-methyl-2H-1,2,3,-triazole was prepared in the same manner as in Example 1 -4-formic acid (compound 3), the total yield is 69% (based on raw material 4-n-butoxy-3-cyanoaniline), its structural formula, 1 H-NMR and MS data are listed in Table-1 below.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicine and relates to 2-(3-cyano/nitro-4-substituted phenyl)-4-methyl-2(i)H(/i)-1,2,3-triazole-4-methane acid and formyl hydrazine compounds shown in the formula I, medicinal salt and medicinal solvate and a preparation method thereof. The substituent definition of the compounds is defined as claim books and manuals. The invention further relates to application of the compounds in preparation of medicine for treatment of hyperuricemia and gout diseases.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to a series of xanthine oxidase inhibitors, in particular to 2-(3-cyano / nitro-4-substituted phenyl)-4-methyl-2H-1,2,3- Triazole-4-carboxylic acid or 2-(3-cyano / nitro-4-substituted phenyl)-4-methyl-2H-1,2,3-triazole-4-carboxhydrazide compounds and its uses. Background technique [0002] Gout is a global metabolic disease, and its prevalence is affected by various factors such as economic development, environment, eating habits, race, genetics, medical level, diagnostic criteria, and statistical methods. Big. In recent years, the prevalence of gout has been increasing year by year no matter in European and American countries or in Asian countries. The prevalence rates of hyperuricemia and gout in my country also show a linear upward trend. According to statistics, the total prevalence rate of gout in all age groups is about 0.84%. [0003] Gout is caused by the excessive production ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D249/06A61K31/4192A61P19/06
CPCC07D249/06
Inventor 张为革石爱龙关奇王赫包凯冯东杰阎殊琦吴越王德发李晓娜
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap